Resource Development Core

资源开发核心

基本信息

  • 批准号:
    10746903
  • 负责人:
  • 金额:
    $ 27.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT - RESOURCE DEVELOPMENT CORE (RDC) The main goal of the University of Michigan O'Brien Kidney Translational Resource Center (MKTC) is to provide an effective translational research pipeline that relies on a systems biology approach to develop novel, diagnostic, prognostic and therapeutic strategies for patients with kidney diseases. Our Resource Development Core (RDC) will support the Applied Systems Biology Core (ASBC), the Data Analytic Services Core (DASC) and the kidney research community at large by developing a unified platform and methods that integrate multidimensional data, cohort selection and clinical trial design. The University of Michigan Precision Health Initiative (PHI), which incorporates all data from Michigan Medicine patients in addition to social determinants of health and biological samples, represents a unique resource that the RDC will expand upon to develop the following pipelines: a. Biomarker candidate selection, assay, validation, and incorporation into study design. The RDC will establish a database and pipeline to provide investigators the most promising biomarkers, relevant assays based on the outcomes investigated, in addition to guidance surrounding validation and quality control. b. Cohort development. We will leverage the infrastructure of the PHI to build algorithms to identify and curate with high confidence kidney-specific diagnoses, relevant clinical characteristics, laboratory testing, social determinants of health, well as outcomes through integrating multiple data sources including billing codes and natural language processing. The end-result will provide investigators the ability to easily identify relevant cohorts and rapidly retrieve data in a format that is ready to analyze through a graphical user interface. c. Kidney outcomes. We will establish a pipeline to incorporate United States Renal Data System (USRDS) data into the PHI platform, enriching the Michigan Medicine dataset and providing confirmatory data for cohort- specific analyses. d. Novel metabolomic technologies and multi-omic integration. In addition to developing spatial metabolomic platform, we improve tools for annotation of untargeted metabolomics data and identification of new compounds and provide novel integrative analysis of metabolomics-proteomics-transcriptomics- epigenomics data. e. Clinical trial design. We will establish a workflow for kidney-specific clinical trial design and implementation, as well as provide associated workshops through the highly successful Clinical Trials Academy. The pipelines and workflows to be established by the RDC will provide investigators across the spectrum of research stages – from bench (biomarker discovery) to bedside (clinical trial design) – the ability to integrate of multidimensional data – from social determinants of health to organic biomarkers and outcomes – in addressing the major challenges the management of patients with kidney disease.
摘要 - 资源开发核心(RDC) 密歇根大学奥布莱恩肾脏翻译资源中心(MKTC)的主要目标是 提供有效的翻译研究管道,依赖于系统生物学方法来开发 针对肾脏疾病患者的新颖,诊断,预后和治疗策略。我们的资源 开发核心(RDC)将支持应用系统生物学核心(ASBC),数据分析服务 核心(DASC)和整个肾脏研究社区通过开发一个统一的平台和方法 综合多维数据,队列选择和临床试验设计。密歇根大学精确 健康计划(PHI),除了社会外,还包含来自密歇根医学患者的所有数据 健康和生物样品的决定因素,代表了RDC将扩展到的独特资源 开发以下管道: 一个。生物标志物的候选,评估,验证和纳入研究设计。 RDC会 建立数据库和管道,为调查人员提供最有前途的生物标志物,相关测定 除了围绕验证和质量控制的指导外,还基于研究结果。 b。队列发展。我们将利用PHI的基础架构来构建算法以识别和策划 具有高度信心的肾脏特异性诊断,相关临床特征,实验室测试,社会 通过整合包括计费代码和的多个数据源来确定健康的结果 自然语言处理。最终结果将使调查人员能够轻松识别相关的能力 以图形用户界面进行分析的格式迅速群体并快速检索数据。 c。肾脏结果。我们将建立一条管道,以合并美国肾脏数据系统(USRDS) 数据到PHI平台,丰富密歇根州医学数据集并为队列提供确认数据 具体分析。 d。新型代谢组技术和多摩变整合。除了发展空间代谢组 平台,我们改善了注释未靶向代谢组学数据的工具和新的识别 化合物并提供新颖的代谢组学 - 蛋白质 - 转录组学 - ebebenomics的综合分析 数据。 e。临床试验设计。我们将建立用于肾脏特异性临床试验设计和实施的工作流程, 以及通过非常成功的临床试验学院提供相关的研讨会。 RDC将建立的管道和工作流将为调查人员提供各种范围 研究阶段 - 从长凳(生物标志物发现)到床旁(临床试验设计) - 整合的能力 多维数据 - 从健康的社会决定者到有机生物标志物和结果 - 应对肾脏疾病患者的管理的主要挑战。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Salim Hayek其他文献

Salim Hayek的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Salim Hayek', 18)}}的其他基金

Extracorporeal SuPAR Extraction to Prevent COVID-19-associated Acute Kidney Injury
体外 SuPAR 提取预防 COVID-19 相关的急性肾损伤
  • 批准号:
    10362860
  • 财政年份:
    2021
  • 资助金额:
    $ 27.84万
  • 项目类别:
Role of SuPAR in the Intersection between Cardiovascular and Kidney Disease
SuPAR 在心血管疾病和肾脏疾病交叉点中的作用
  • 批准号:
    10198038
  • 财政年份:
    2020
  • 资助金额:
    $ 27.84万
  • 项目类别:
Role of SuPAR in the Intersection between Cardiovascular and Kidney Disease
SuPAR 在心血管疾病和肾脏疾病交叉点中的作用
  • 批准号:
    10670320
  • 财政年份:
    2020
  • 资助金额:
    $ 27.84万
  • 项目类别:
Role of SuPAR in the Intersection between Cardiovascular and Kidney Disease
SuPAR 在心血管疾病和肾脏疾病交叉点中的作用
  • 批准号:
    10029263
  • 财政年份:
    2020
  • 资助金额:
    $ 27.84万
  • 项目类别:
Role of SuPAR in the Intersection between Cardiovascular and Kidney Disease
SuPAR 在心血管疾病和肾脏疾病交叉点中的作用
  • 批准号:
    10450750
  • 财政年份:
    2020
  • 资助金额:
    $ 27.84万
  • 项目类别:

相似海外基金

Particulate exposure and kidney health: Diversity Supplement Villarreal Hernandez
颗粒物暴露与肾脏健康:多样性补充剂 Villarreal Hernandez
  • 批准号:
    10770032
  • 财政年份:
    2023
  • 资助金额:
    $ 27.84万
  • 项目类别:
Ceramides as Novel Mediators of Tubular Metabolic Dysfunction Driving Kidney Injury
神经酰胺作为肾小管代谢功能障碍驱动肾损伤的新型调节剂
  • 批准号:
    10677394
  • 财政年份:
    2023
  • 资助金额:
    $ 27.84万
  • 项目类别:
SCH: Artificial Intelligence enabled multi-modal sensor platform for at-home health monitoring of patients
SCH:人工智能支持的多模式传感器平台,用于患者的家庭健康监测
  • 批准号:
    10816667
  • 财政年份:
    2023
  • 资助金额:
    $ 27.84万
  • 项目类别:
Acute Kidney Injury in Children with Chronic Kidney Disease
慢性肾病儿童的急性肾损伤
  • 批准号:
    10638267
  • 财政年份:
    2023
  • 资助金额:
    $ 27.84万
  • 项目类别:
Wearable alert system for detecting postoperative hypotension
用于检测术后低血压的可穿戴警报系统
  • 批准号:
    10760370
  • 财政年份:
    2023
  • 资助金额:
    $ 27.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了